About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Clinicaltrials.gov identifier NCT03923556

Recruitment Status Recruiting

First Posted April 22, 2019

Last update posted August 20, 2020

Study Description

Brief summary:

The purpose of this study is to compare two medications that reverse muscle paralysis at the end of kidney transplant surgery with the goal of reducing residual muscle weakness and insufficient respiratory function after surgery.

  • Condition or Disease:Kidney Transplant; Complications
    Postoperative Residual Curarization
    Postoperative Residual Weakness
  • Intervention/Treatment: Drug: Sugammadex
    Drug: Neostigmine
  • Phase: Phase 4
Detailed Description

This is a prospective randomized double-blind single center study on patients with severe kidney failure undergoing kidney transplantation surgery. Patients will have their muscles paralyzed during general anesthesia for surgery. At the end of surgery, muscle paralysis will be reversed with either neostigmine (control group) or sugammadex (intervention group). Residual muscle weakness and respiratory function will be monitored after surgery with a quantitative train-of-four (qTOF) monitor and a noninvasive continuous ventilation monitor. The investigators hypothesize that patients receiving sugammadex will have less residual muscle weakness and better respiratory function than patients receiving neostigmine. Respiratory and kidney function parameters and any adverse events will be collected during the hospital stay. Patients will contacted for a study follow up around 2 weeks after their surgery.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: A Double-blind, Randomized, Parallel Study to Compare the Efficacy of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery in Patients With Severe Kidney Dysfunction
  • Estimated Study Start Date: September 2020
  • Estimated Primary Completion Date: April 2022
  • Estimated Study Completion Date: May 2022
Arms and interventions
Arm Intervention/treatment
Experimental: Sugammadex
Sugammadex
Drug: Sugammadex
Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
Active Comparator: Neostigmine
Neostigmine
Drug: Neostigmine
Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
Outcome Measures
  • Primary Outcome Measures: 1. Hypoventilation in post-anesthesia care unit (PACU) [ Time Frame: Within up to 3 hours after the end of surgery ]
    Presence of one or more episodes of hypoventilation in PACU, adjusted to qTOF and other confounders
  • Secondary Outcome Measures: 1. Duration of surgery [ Time Frame: During operating room stay ]
    Intraoperative minutes from surgical incision to closure (duration of surgery)
  • 2. Time from NMBR administration to adequate NMBR [ Time Frame: Within minutes from NMBR administration intraoperatively ]
    Intraoperative minutes from NMBR administration to qTOF T4/T1 equal or greater than 0.9
  • 3. Time from NMBR administration to tracheal extubation [ Time Frame: Within minutes from NMBR administration intraoperatively ]
    Intraoperative minutes from NMBR administration to tracheal extubation
  • 4. Duration of anesthesia [ Time Frame: During operating room stay ]
    Intraoperative minutes from tracheal intubation to tracheal extubation (duration of anesthesia)
  • 5. Presence of qTOF <0.9 in PACU [ Time Frame: Within up to 3 hours after the end of surgery ]
    Incidence of qTOF <0.9 in PACU
  • 6. Number of events of hypoventilation in PACU [ Time Frame: Within up to 3 hours after the end of surgery ]
    Number of events of hypoventilation lasting 1 minute or longer in PACU
  • 7. Accumulated minutes of hypoventilation in PACU [ Time Frame: Within up to 3 hours after the end of surgery ]
    Accumulated minutes of hypoventilation in PACU
  • 8. Delayed postoperative hypoventilation [ Time Frame: Within up to 3 postoperative days, counting from PACU discharge ]
    Presence of one or more episodes of hypoventilation in postoperative floor, adjusted to qTOF and other confounders
  • 9. Number of events of delayed postoperative hypoventilation [ Time Frame: Within up to 3 postoperative days, counting from PACU discharge ]
    Number of events of hypoventilation lasting 1 minute or longer in the postoperative floor
  • 10. Accumulated minutes of delayed postoperative hypoventilation [ Time Frame: Within up to 3 postoperative days, counting from PACU discharge ]
    Accumulated minutes of hypoventilation in the postoperative floor
  • 11. qTOF <0.9 in postoperative floor [ Time Frame: Within up to 3 postoperative days, counting from PACU discharge ]
    Delayed detection of qTOF <0.9 in postoperative floor
  • 12. Presence of postoperative pulmonary complications [ Time Frame: Within up to 3 postoperative days and at 14 +/- 3 days after surgery ]
    Presence of predefined postoperative pulmonary complications, including respiratory failure, reintubation, ARDS, pneumonia, pneumothorax, atelectasis, pleural effusion or bronchospasm.
  • 13. Dyspnea functional limitation [ Time Frame: Within up to 14 +/- 3 days after surgery ]
    Score on standardized Patient-Reported Outcomes Measurement Information System (Promis) dyspnea functional limitation questionnaire score, compared to patient's baseline. Functional measurements include walking, lifting and activities of daily living. The higher the score on this instrument the more functional limitation (scale range is from 0 to 30)
  • 14. Kidney graft function as measured by postoperative plasma clearance of creatinine (ClCr) [ Time Frame: Within up to 3 postoperative days and at 14 +/- 3 days after surgery ]
    Predefined kidney graft function based on postoperative ClCr
  • 15. Number of participants with kidney graft dysfunction [ Time Frame: Within up to 3 postoperative days and at 14 +/- 3 days after surgery ]
    Predefined kidney graft negative outcomes including: postoperative increasing ClCr, reduced daily urine output, need for dialysis postoperatively, and/or diagnosis of delayed graft function or kidney graft rejection.
  • 16. Rate of adverse events [ Time Frame: Within up to 3 postoperative days ]
    Adverse events related to NMBR medications, including hypersensitivity and any other adverse events
  • 17. Hospital resources utilization: total operating room time [ Time Frame: During operating room stay ]
    Hospital resources utilization parameters, including total operating room time
  • 18. Hospital resources utilization: PACU stay duration [ Time Frame: During PACU stay ]
    Hospital resources utilization parameters, including total PACU stay duration
  • 19. Hospital resources utilization: Hospital length of stay [ Time Frame: Within up to 14 +/- 3 days after surgery ]
    Hospital resources utilization parameters, including total hospital stay duration
  • 20. Hospital resources utilization: Rate of ICU admission [ Time Frame: Within up to 14 +/- 3 days after surgery ]
    Hospital resources utilization parameters, including the need of ICU admission
  • 21. Hospital resources utilization: ICU length of stay [ Time Frame: Within up to 14 +/- 3 days after surgery ]
    Hospital resources utilization parameters, including total ICU stay duration
Eligibility Criteria
  • Ages Eligible for Study: 18 to 90 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- At least 18 years or older

- Diagnosed with severe kidney dysfunction (defined by plasma creatinine clearance 40 kg/m2

- Pre-existing oxygen or ventilatory dependency (24h use of oxygen or other noninvasive
or invasive ventilatory support)

- Patients with any pulmonary, neuromuscular or other disease that severely limits their
respiratory functional status (e.g. unable to achieve 4 Metabolic Equivalent of Tasks,
METs, such as climbing up 1 flight of stairs)

- Presence of any contraindication for any of the study-related medications or
interventions.

Contacts and Locations
Contacts

Contact: Ana Fernandez-Bustamante, M.D., Ph.D. 303-724-2935 ana.fernandez-bustamante@cuanschutz.edu

Locations

United States, Colorado
University of Colorado Hospital
Aurora

Sponsors and Collaborators

University of Colorado, Denver

Investigators

Principal Investigator: Ana Fernandez-Bustamante, M.D., Ph.D. University of Colorado School of Medicine

More Information
  • Responsible Party: University of Colorado, Denver
  • ClinicalTrials.gov Identifier: NCT03923556 History of Changes
  • Other Study ID Numbers: 18-2707
  • First Posted: April 22, 2019 Key Record Dates
  • Last Update Posted: August 20, 2020
  • Last Verified: August 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Delayed Emergence from Anesthesia